Pay in 4 interest-free payments of $5.60 Learn more
Ships within 48 hours · Estimated delivery Aug 31 - Sep 5
At the end of the day, Larkin is not about forcing plans to cover GLP-1s or preventing them from doing so
Daniell went to buy her boyfriend a birthday present at a soccer store and walked out with a pair of indoor shoes for herself
doi:10.3390/nu11112611 Shi Q, Nong K, Vandvik PO, et al
We are executing with focus and discipline, and the momentum across our programs continues to accelerate as we move closer to bringing this product candidate to patients who need it most. Advancing Toward Value-Driving Catalysts in 2026 Fractyl is advancing toward multiple anticipated clinical readouts from the ongoing REMAIN weight maintenance program: January 2026: 6-month randomized data from the REMAIN-1 Midpoint Cohort Q2 2026: 1-year REVEAL-1 Cohort data Q3 2026: 1-year REMAIN-1 Midpoint Cohort data H2 2026: Topline 6-month randomized data from REMAIN-1 Pivotal Cohort H2 2026: Potential Revita PMA filing in post-GLP-1 weight maintenance About REVEAL-1 The REVEAL-1 Cohort (n=22) is an open-label study in individuals living with obesity who have lost at least 15% of their total body weight on a GLP-1 medication and who either need or choose to discontinue GLP-1 therapy
